(5) चालू वर्ष (1993-94) के दौरान स्वदेशी रूप से निर्मित डी ए पी, आयातित एम ओ पी पर 1000 रुपये प्रति टन की रियायत तथा काम्पलैक्स उर्वरकों की बिक्री पर तदनुरूपी रियायत जिससे कि उन्हें उनके न्यूट्रिएन्ट अंश के अनुपात में किया जा सके तथा सिंगल सुपर फास्फेट पर 340 रुपए प्रति टन की रियायत की एक योजना चालू की गयी है। यह रियायत आयातित डी ए पी अथवा काम्पलैक्स उर्वरकों पर उपलब्ध नहीं है।

Appeal Against Rule SO—A of IDPL/ CDA Roles

3104. SHRI MD. SALIM : Will the PRIME MINISTER be pleased to refer to the reply to the Unstarred Question 2908 given in Rajya Sabha on 18th March, 1993 and state :

(a) what were the reasons which were recorded in writing by the Screening Committee and who were the members of the said Committee with details thereof;

(b) wiiether an employee has the right to know the complete rule which is concerning him and his future career, with reasons therefor ;

(c) the reasons as to how an employes of the company would know in the absence of any indication on the rale concerning him and which has not been a specified on it ;

(d) whether such indications as (c) above are to be kept in the files of the company and hidden from the employees and disclosed only if pointed out to the company, together with reasons, therefor ; and

(e) what is the fate of the representation of the said official which was sent to the Board of Directors on the 3rd September, 1992?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a) to (e) The question relates to a former Marketing Executive of IDPL whose services were terminated by the company in accordance with the provisions of Conduct, Discipline & Appeal Rules of the company. For employees below the Board level, Government is neither the Appointing, Disciplinary, Appellate nor the Reviewing Authority and as such the Government does not intervene in the service matters of such employees of the public sector undertakings.

The company has reported that the said employee had filed a Writ Petition in the Hon'ble Delhi High Court against the disciplinary proceedings initiated against him by the management and the Writ Petition was dismissed by the Hon'ble Delhi High Court. While dismissing the petition, the Hon'ble Delhi High Court observed "The petitioner has been unauthorisedly abstaining himself from joining since March, 1989. This is nothing short of indiscipline. In these circumstances, we are not inclined to interfere. Dismissed." Aggrieved by these orders of the High Court, the petitioner filed two Special Leave Petitions in the Hon'ble Supreme Court of India which were also rejected.

Production of Betamethasone by M/s. Glaxo

3105. PROF. I. G. SANADI : Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that M/s. Glaxo is the only producer formulator of Betamethasone;

(b) whether it is a fact that unintended benefit of Rs. 16 crores per annum is given to the company by notionally allowing 8 per cent incidents when there are no followers of their packs in the organised sactor, if so, what is the justification therefor;

(c) what are the names of other drugs and companies falling under same situation and what steps have been taken to rectify the position ; and

(d) whether it is a fact that Methdi-lazine, Cepheloridine and several bulk drugs and formulations of Glaxo have been price decontrolled without any basis, if so, the reasons thereof ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a) to (d) The information is being collected and will be laid on the Table of the House.

Delicensing of Pharmaceutical Industry

3106. SHRI G. G. SWELL: Will the PRIME MINISTER be pleased to state :

(a) whether it is a fact that in a recent seminar in New Delhi on "Price control on the Pharmaceutical Industry" he said that Government was in the process of delicensing the pharmaceutical industry ;

(b) whether before making the state ment he had considered the fallout on price of the product patent regime under GATT which will come into effect in the near future :

(c) whether many American patents relating to i^any drugs and pharmaceuticals in India are in the pipeline and need not wait the 10 years grace period;